

VERTEX PHARMA - Dependence on Success of its CF Pipeline = Risk

https://marketpublishers.com/r/V04BD4A0478EN.html

Date: April 2013 Pages: 4 Price: US\$ 140.00 (Single User License) ID: V04BD4A0478EN

Abstracts

Vertex Pharma's (VRTX) stock has moved up ~30% in this year mostly based on the positive expectation building on Lumacaftor/KALYDECO (CFTR corrector/ CFTR potentiator, PhIII, homozygous del508 mutation Cystic fibrosis/CF), after it received breakthrough therapy designation from the FDA. VRTX entered into three non-exclusive agreements to conduct PhII IFN-free PoC studies of VX-135 in combination with BMY's daclatasvir (NS5A Inhivitor, PhII), JNJ/MVIR's Simeprevir (PI, PhII) and with GSK's GSK2336805, (NS5A inhibitor, PhII) but the competition are way ahead and after risk reward analysis of the pipeline, there remains limited.....For more detail, please read our report released on 9th March, 2013 on Vertex titled "Dependence on Success of its CF Pipeline = Risk!"

Companies mentioned

Vertex Pharma



I would like to order

Product name: VERTEX PHARMA - Dependence on Success of its CF Pipeline = Risk Product link: <u>https://marketpublishers.com/r/V04BD4A0478EN.html</u>

> Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/V04BD4A0478EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970